Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2024-06-28 Declaration of Voting R…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a company announcement from Zealand Pharma A/S, dated June 28, 2024, titled "Total number of shares and voting rights in Zealand Pharma at June 28, 2024." It explicitly states the total number of shares and voting rights following recent capital increases (warrant exercise and directed issue). This type of announcement, detailing changes in the total number of shares outstanding, is directly related to the company's capital structure. While it mentions capital increases (CAP), the core purpose is a mandatory disclosure regarding the current share count, which often falls under general regulatory reporting or capital structure updates. Given the options, it is most closely related to a change in share capital or a general regulatory disclosure. Since it is a specific announcement about the total share count following capital changes, it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were less specific. However, because it details the result of capital changes (exercise of warrants and directed issue), CAP is a strong candidate. Alternatively, since it is a mandatory disclosure under the Danish Capital Markets Act regarding share capital, and it is not a full report, it could be RNS. Reviewing the definitions, 'Share Issue/Capital Change (SHA)' relates to the announcement of the issue itself, while 'Capital/Financing Update (CAP)' covers financing activities or capital structure changes. This document reports the *result* of capital changes. Given the nature of mandatory disclosure of share count, and the lack of a specific 'Share Count Disclosure' code, RNS (Regulatory Filings) serves as the appropriate general regulatory disclosure category for mandatory updates that don't fit perfectly elsewhere, especially since it references compliance with the Danish Capital Markets Act. However, since the text explicitly references prior announcements about 'exercise of employee warrants' and 'completed registration of a capital increase', it is fundamentally about the resulting capital structure. I will classify it as RNS as it is a routine, mandatory disclosure of share count, which is a common function of general regulatory announcements, rather than a specific financing event announcement (CAP/SHA).
2024-06-28 English
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement titled "Zealand Pharma completes registration of capital increase." It explicitly details the registration of a capital increase involving 8,350,000 new shares with the Danish Business Authority. This action directly relates to changes in the company's capital structure and financing activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it announces the finalization of a capital increase resulting from a directed issue/private placement.
2024-06-28 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 99% confidence The document is a company announcement from Zealand Pharma detailing the completion of an 'upsized equity offering' of new ordinary shares, raising significant gross proceeds (USD 1 billion / DKK 7 billion). Key phrases include 'announces completion of an upsized equity offering,' 'increase the share capital by issuing 8,350,000 new shares,' and 'total gross proceeds from the Offering will amount to USD 1 billion / DKK 7 billion.' This directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a share repurchase (POS) as it is an issuance of new shares to raise capital.
2024-06-26 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 99% confidence The document is an official company announcement from Zealand Pharma regarding the 'upsizing of previously announced equity offering' from USD 900 million to USD 1 billion. It details the process, expected timetable for settlement and listing of new shares, and includes extensive legal disclaimers typical of a securities offering. This activity—raising capital through the issuance of new shares—falls directly under the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains the substantive details of the financing event itself.
2024-06-25 English
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement from Zealand Pharma detailing the launch of an equity offering to raise approximately USD 900 million through the issuance of new shares via an accelerated bookbuilding process. This action directly relates to fundraising, financing activities, and changes in the company's capital structure (issuance of new shares). This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it involves share issuance (SHA) and could potentially be a general regulatory filing (RNS), the primary focus and purpose described is the capital raise itself, making CAP the most specific and accurate classification.
2024-06-25 English
Regulatory Filings 2024
Regulatory Filings Classification · 99% confidence The document is titled 'Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial...' and is explicitly labeled as a 'Company announcement – No. 32 / 2024'. It details clinical trial results (Phase 1b topline data) and announces an upcoming conference call to discuss these results. This structure—announcing key results and scheduling a call—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on clinical trial results and not comprehensive quarterly financials, it aligns best with the 'Earnings Release' category, which often covers key operational highlights preceding a formal financial report, or a general announcement of significant news. Given the options, 'ER' (Earnings Release) is the closest fit for a major, time-sensitive announcement of clinical trial success that drives investor interest, even if it's not a standard quarterly financial report. It is not a full report (10-K, IR), a presentation (IP), or just a notice of publication (RPA).
2024-06-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.